Physician profile
Vincent E Herrin
NPI 1558396424
$1,007,638.06
in general payments reported to CMS, 2019-2025
72 companies · $98K in 2025
The $98K reported for 2025 was more than what 98% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317K · 2020: $91K · 2021: $111K · 2022: $156K · 2023: $153K · 2024: $81K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $262K · Consulting Fee: $30K · Travel and Lodging: $28K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $261,967.50 |
| Consulting Fee | $29,510.00 |
| Travel and Lodging | $27,978.86 |
| Food and Beverage | $12,634.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $342,682.18 | 2019-2025 | Lunsumio, Polivy, Columvi |
| Seagen INC. | $201,470.54 | 2019-2023 | Adcetris |
| Abbvie INC. | $164,946.69 | 2019-2025 | |
| Janssen Biotech, INC. | $95,703.85 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $79,922.55 | 2019-2025 | Iclusig, Alunbrig, Fruzaqla |
| Pfizer INC. | $62,435.74 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $33,141.80 | 2019-2023 | Epkinly, Imbruvica |
| Genzyme Corporation | $9,976.76 | 2019-2025 | |
| Kite Pharma, INC. | $9,937.89 | 2021-2025 | Yescarta |
| Celgene Corporation | $1,054.98 | 2019-2025 | Reblozyl, Breyanzi, Pomalyst |
| Incyte Corporation | $657.21 | 2019-2025 | Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $480.70 | 2019-2025 | Keytruda, Prevymis, Lynparza |
| Novartis Pharmaceuticals Corporation | $478.04 | 2019-2025 | |
| Amgen INC. | $364.29 | 2019-2022 | |
| Daiichi Sankyo INC. | $354.11 | 2022-2025 | Vanflyta, Enhertu, Injectafer |
Show all 71 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Herrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.